|  |
| 个人简介 |  |
| 2001.09 – 2005.06，山东大学药学院，药学学士； 2005.09 – 2010.07，中国科学院上海药物研究所，药物化学博士（导师：杨玉社）； 2010.07 – 2013.10，上海汇伦生命科技有限公司，高级研究员、部门经理； 2013.11 – 2016.03，美国伊利诺伊大学芝加哥校区，博士后（导师：Alan P. Kozikowski）； 2016.03至今，上海科技大学iHuman研究所，Research Associate Professor 、PI。 |
| 主要研究内容 | |
| 1. 靶向GPCR的药物发现。针对与人类重大疾病（如肿瘤和中枢神经系统疾病）相关的G蛋白偶联受体（GPCR）开展药物化学研究，设计、合成类药性化合物并进行生物活性研究和成药性评价。 2. 偏向型GPCR配体。针对特定的GPCR受体，设计合成偏向型配体，并进行作用机制研究，探讨GPCR偏向型信号通路的作用特点和结构基础。 |
| 代表性论文 | |
| 1. Tan, L; Yan, W.; McCorvy, J. D.;* Cheng, J.* Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. J Med Chem 2018, 61, 9841−9878. 2. Peng, Y.; McCorvv, J. D.; Harpsoe, K.; Lansu, K.; Yuan, S.; Popov, P.; Qu, L.; Pu, M.; Che, T.; Nikolajsen, L. F.; Huang, X.-P.; Wu, Y.; Shen, L.; Bjorn-Yoshimoto, W. E.; Ding, K.; Wacker, D.; Han, G. W.; Cheng, J.; Katritch, V.; Jensen, A. A.; Hanson, M. A.; Zhao, S.; Gloriam, D. E.; Roth, B. L.;* Stevens, R. C.;* Liu, Z.-J.* 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell 2018, 172, 719–730. 3. Pogorelov, V. M.; Rodriguiz, R. M.; Cheng, J.; Huang, M.; Schmerberg, C. M.; Meltzer, H. Y.; Roth, B. L.; Kozikowski, A. P.; Wetsel, W. C.* 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology 2017, 42, 2163–2177. 4. Zhang, G.; Cheng, J.; McCorvy, J. D.; Lorello, P. J.; Caldarone, B. J.; Roth, B. L.; Kozikowski, A. P.* Discovery of N‑Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. J Med Chem 2017, 60, 6273−6288. 5. Cheng, J.; McCorvy, J. D.; Giguere, P. M.; Zhu, H.; Kenakin, T.; Roth, B. L.;* Kozikowski, A. P.* Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists. J Med Chem 2016, 59, 9866−9880. 6. Cheng, J.; Giguere, P. M.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Huang, X.-P.; Zhu, H.; McCorvy, J. D.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P.* Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. J Med Chem, 2016, 59, 578–591. 7. Cheng, J.; Kozikowski, A. P.* We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. ChemMedChem 2015, 10, 1963–1967. 8. Cheng, J.; Giguere, P. M.; Onajole, O. K.; Lv, W.; Gaisin, A.; Gunosewoyo, H.; Schmerberg, C. M.; Pogorelov, V. M.; Rodriguiz, R. M.; Giulio Vistoli, G.; Wetsel, W. C.; Roth, B. L.; Kozikowski, A. P.* Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. J Med Chem, 2015, 58, 1992–2002. 9. Cheng, J.; Giguere, P. M.; Lv, W.; Roth, B. L.; Kozikowski, A. P.* Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)-methanamine as a Selective Serotonin 2C Agonist. Tetrahedron Lett, 2015, 56, 3420–3422. 10. Cheng, J.;* Qin, J.; Guo, S.; Qiu, H.; Zhong, Y. Design, Synthesis and Evaluation of Novel HDAC Inhibitors as Potential Antitumor Agents. Bioorg Med Chem Lett 2014, 24, 4768–4772. |
